Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review
- PMID: 33796989
- DOI: 10.1007/s11033-021-06318-9
Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review
Abstract
Increased deaths caused due to pancreatic cancer (PC) is drawing much attention towards an immediate need for therapeutics that could possibly control this disease and increase the patients' survival rate. Despite the long list of well-established chemotherapeutic drugs in several cancers none have proved to be efficient against PC, and the increasing chemoresistance to the gold standard drug gemcitabine calls a need to search for solutions in other categories of drug. To the rescue, antifungals have shown themselves to be effective against PC and can increase gemcitabine sensitivity against PC. In this mini-review, we reported how antifungals have targeted PC and helped to reduce its lethality. Additionally, it is emphasized that how the antifungals show new mechanisms that could be triggered by using either monotherapy or combination therapy of these antifungals with chemotherapeutic drugs in PC. Moreover it shows an approach of using other drugs with possible same or other mechanism to know their effect on PC.
Keywords: Antifungal; Chemoresistance; Drug repurposing; Gemcitabine; Pancreatic ductal adenocarcinoma.
Similar articles
-
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044. Epub 2016 Mar 31. Biomaterials. 2016. PMID: 27082874 Free PMC article.
-
Integrated genomic analysis to identify druggable targets for pancreatic cancer.Front Oncol. 2022 Dec 1;12:989077. doi: 10.3389/fonc.2022.989077. eCollection 2022. Front Oncol. 2022. PMID: 36531045 Free PMC article.
-
Molecular Targeted Intervention for Pancreatic Cancer.Cancers (Basel). 2015 Aug 10;7(3):1499-542. doi: 10.3390/cancers7030850. Cancers (Basel). 2015. PMID: 26266422 Free PMC article. Review.
-
Antifungals: Uncovering new drugs and targets.Nat Rev Microbiol. 2017 Jan;15(1):1. doi: 10.1038/nrmicro.2016.179. Epub 2016 Nov 21. Nat Rev Microbiol. 2017. PMID: 27867200 No abstract available.
-
Repurposing Tuft Cells to Suppress Pancreatic Cancer.Cell Mol Gastroenterol Hepatol. 2021;11(2):659-660. doi: 10.1016/j.jcmgh.2020.09.009. Epub 2020 Oct 10. Cell Mol Gastroenterol Hepatol. 2021. PMID: 33049247 Free PMC article. No abstract available.
Cited by
-
Ionic resorcinarenes as drug solubilization agents in water.RSC Adv. 2024 Oct 28;14(46):34228-34238. doi: 10.1039/d4ra06682k. eCollection 2024 Oct 23. RSC Adv. 2024. PMID: 39469002 Free PMC article.
References
-
- Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R et al (2007) Global cancer facts and figures. American Cancer Society, Atlanta
-
- Wiest NE, Moktan VP, Oman SP, Chirilă RM (2020) Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 58(3):119–128. https://doi.org/10.2478/rjim-2020-0009 - DOI - PubMed
-
- Gašić U, Ćirić I, Pejčić T, Radenković D, Djordjević V, Radulović S et al (2020) Polyphenols as possible agents for pancreatic diseases. Antioxidants (Basel) 9(6):547. https://doi.org/10.3390/antiox9060547 - DOI
-
- Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H (2019) Chemoresistance in pancreatic cancer. Int J Mol Sci 20(18):4504 - DOI
-
- Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV (2020) Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 12(2):173–181. https://doi.org/10.4251/wjgo.v12.i2.173 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical